Loading...
Market
Story
Moderna Beats Q1 Estimates, Plans RSV Vaccine Launch Despite Revenue Drop
May 2, 2024, 12:05 PM
Moderna Inc. reported first-quarter earnings that surpassed analyst expectations, with earnings per share of $(3.07) beating estimates of $(3.55) and sales totaling $167 million, exceeding the forecast of $97.5 million. The company's revenue, however, saw a significant decline of 91% compared to the previous year, primarily due to a drop in Covid vaccine sales. Despite the decline, the revenue still topped expectations. Moderna's Spikevax vaccine generated $167 million in sales, including $100 million in U.S. sales and $67 million internationally. The company also announced plans to launch an RSV vaccine in the fall.
View original story
Similar markets
More than 20% • 50%
20% or less • 50%
Moderna leads • 33%
GSK leads • 33%
Pfizer leads • 33%
Below $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
Above $1.5 billion • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Novavax • 25%
Above $500 million • 50%
Below $500 million • 50%
More than GSK and Pfizer combined • 50%
Less than GSK and Pfizer combined • 50%
Moderna gains highest market share • 33%
Pfizer retains highest market share • 33%
BioNTech gains highest market share • 33%
Novavax/Sanofi leads • 33%
Pfizer/BioNTech leads • 33%
Moderna leads • 33%